Diamyd Medical accelerates primary efficacy readout by 9 months in type 1 diabetes phase 3 trial following US FDA alignment and guidance

Diamyd Medical, a company develops precision medicine therapies to prevent and treat type 1 diabetes through innovative research and clinical development, has reached alignment with the US Food and Drug Administration (FDA) to accelerate the primary efficacy readout in its ongoing pivotal, registrational phase 3 DIAGNODE-3 trial in type 1 diabetes from 24 to 15 months, per FDA guidance, enabling the full primary efficacy readout of the trial to occur nine months earlier than previously planned and communicated. 

The previously announced interim efficacy readout, involving approximately 170 participants with 15-month data, remains on track for the end of March 2026 and may support an accelerated BLA pathway, consistent with FDA guidance.

“We are very pleased with the FDA’s feedback as it provides a clear way forward,” says Ulf Hannelius, CEO of Diamyd Medical. “The proposed change meaningfully shortens the timeline to the full primary efficacy readout in our registrational phase 3 trial, while maintaining a robust assessment of long-term efficacy. We remain focused on the upcoming interim efficacy readout in March 2026, which is on track as the next key catalyst in our efforts to bring this therapy to patients with type 1 diabetes.”

The trial’s co-primary efficacy endpoints, C-peptide area under the curve (AUC), a marker of endogenous insulin production, and HbA1c, a measure of blood sugar control, were originally defined at 24 months. Following a recent Type C meeting, and consistent with FDA guidance, the FDA agreed with the Company’s proposal to change the timepoint for the primary efficacy readout to 15 months, with a formal protocol amendment to be submitted for FDA review. The originally planned 24-month assessment will be retained as a secondary endpoint to assess durability of the treatment effect of Diamyd.

DIAGNODE-3 is a randomized, double-blind, placebo-controlled Phase 3 trial evaluating Diamyd in approximately 300 genetically defined individuals with stage 3 type 1 diabetes. Diamyd is a precision-medicine, antigen-specific immunotherapy designed to preserve endogenous insulin production.

The FDA has granted Fast Track Designation for Diamyd across Stages 1–3 of type 1 diabetes, Orphan Drug Designation for Stage 3 type 1 diabetes, and has confirmed C-peptide as an acceptable surrogate endpoint that may support an accelerated approval pathway in the United States.

Diamyd Medical develops precision medicine therapies to prevent and treat type 1 diabetes. Diamyd is an investigational antigen-specific immunomodulatory therapeutic for the preservation of endogenous insulin production specifically for individuals carrying an HLA DR3-DQ2 gene.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!